Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2017, Article ID 6218129, 5 pages
Clinical Study

Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

1Saiyu Kawaguchi Clinic, Kawaguchi, Japan
2Saitama Honoka Clinic, Saitama, Japan
3Saiyu Souka Clinic, Souka, Japan

Correspondence should be addressed to Hiroya Takami; pj.oc.oohay@amurad4545amurad

Received 14 February 2017; Revised 13 May 2017; Accepted 20 July 2017; Published 22 August 2017

Academic Editor: Laszlo Rosivall

Copyright © 2017 Hiroya Takami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from  mg to  mg (), and mean serum phosphorus decreased from  mg/dl to  mg/dl (). At 1 month, the corrected calcium and serum phosphorus levels were  mg/dl and  mg/dl, respectively. At 1 year, BMD increased by 2.6%  ± 4.4% in the denosumab group and decreased by 4.5%  ± 7.7% in the control group (). In our observational study, denosumab therapy represents an effective treatment for male dialysis patients with low BMD.